# First Line Hepato Cellular Carcinoma (HCC)

> **NCT00858871** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1714 (actual)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** Brivanib
- **DRUG:** Placebo
- **DRUG:** Sorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00858871
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-06
- **Final completion:** 2013-09
- **Target enrollment:** 1714 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858871, "First Line Hepato Cellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00858871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*